Home
Contact Us
2023 Annual Meeting
facebook
twitter
linkedin
menu
Menu
About Us
Show sub menu
arrow-down
Mission
Members
Board of Directors
Staff
Work at ACLA
COVID-19
Economic Impact
Issues
Show sub menu
arrow-down
Laboratory Innovation & Operations
Saving Access to Lab Services
Regulatory Issues
Reimbursement & Coverage
Value of Clinical Labs
Take Action
Newsroom
Show sub menu
arrow-down
ACLA Blog
ACLA Press Releases
Comments and Letters
Spotlight on Lab Professionals
All News
Member Resources
Show sub menu
arrow-down
ACLA Member SALSA Toolkit
CPT Committee
Prior Authorization Work Group
Join Us
Close Menu
cross
Home
Contact Us
2023 Annual Meeting
About Us
Show sub menu
arrow-down
Mission
Members
Board of Directors
Staff
Work at ACLA
COVID-19
Economic Impact
Issues
Show sub menu
arrow-down
Laboratory Innovation & Operations
Saving Access to Lab Services
Regulatory Issues
Reimbursement & Coverage
Value of Clinical Labs
Take Action
Newsroom
Show sub menu
arrow-down
ACLA Blog
ACLA Press Releases
Comments and Letters
Spotlight on Lab Professionals
All News
Member Resources
Show sub menu
arrow-down
ACLA Member SALSA Toolkit
CPT Committee
Prior Authorization Work Group
Join Us
Home
|
Issues
|
Reimbursement and Coverage
|
ACLA Comment Letter on Reconsideration Request for New Therapeutic Drug and Molecular Pathology CPT Codes
ACLA Comment Letter on Reconsideration Request for New Therapeutic Drug and Molecular Pathology CPT Codes
January 20, 2021
Categories:
Issues
,
Reimbursement and Coverage
Download (PDF, 219KB)
Print page / Save as PDF
